201 related articles for article (PubMed ID: 10481067)
21. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.
Moers C; Warskulat U; Müschen M; Even J; Niederacher D; Josien R; Koldovsky U; Beckmann MW; Häussinger D
Int J Cancer; 1999 Feb; 80(4):564-72. PubMed ID: 9935158
[TBL] [Abstract][Full Text] [Related]
22. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
[TBL] [Abstract][Full Text] [Related]
23. Differential and mutually exclusive expression of CD95 and CD95 ligand in epithelia of normal pancreas and chronic pancreatitis.
Hasel C; Rau B; Perner S; Sträter J; Möller P
Lab Invest; 2001 Mar; 81(3):317-26. PubMed ID: 11310825
[TBL] [Abstract][Full Text] [Related]
24. Differential susceptibility to HIV-GP120-sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: role of CD95/CD95L interactions.
Accornero P; Radrizzani M; Delia D; Gerosa F; Kurrle R; Colombo MP
Blood; 1997 Jan; 89(2):558-69. PubMed ID: 9002959
[TBL] [Abstract][Full Text] [Related]
25. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma.
Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U
Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098
[TBL] [Abstract][Full Text] [Related]
26. The regulation of CD95 (Fas) ligand expression in primary T cells: induction of promoter activation in CD95LP-Luc transgenic mice.
Norian LA; Latinis KM; Eliason SL; Lyson K; Yang C; Ratliff T; Koretzky GA
J Immunol; 2000 May; 164(9):4471-80. PubMed ID: 10779747
[TBL] [Abstract][Full Text] [Related]
27. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.
Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ
Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183
[TBL] [Abstract][Full Text] [Related]
28. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
29. A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation.
Li-Weber M; Laur O; Hekele A; Coy J; Walczak H; Krammer PH
Eur J Immunol; 1998 Aug; 28(8):2373-83. PubMed ID: 9710215
[TBL] [Abstract][Full Text] [Related]
30. Defining CD95 as a tumor suppressor gene.
Müschen M; Warskulat U; Beckmann MW
J Mol Med (Berl); 2000; 78(6):312-25. PubMed ID: 11001528
[TBL] [Abstract][Full Text] [Related]
31. Lens epithelial cells express CD95 and CD95 ligand treatment induces cell death and DNA fragmentation in vitro.
Hueber A; Eichholtz CD; Kociok N; Esser JM; Esser PJ
Eur J Ophthalmol; 2003 Apr; 13(3):241-5. PubMed ID: 12747644
[TBL] [Abstract][Full Text] [Related]
32. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons.
Hosaka N; Oyaizu N; Kaplan MH; Yagita H; Pahwa S
J Infect Dis; 1998 Oct; 178(4):1030-9. PubMed ID: 9806031
[TBL] [Abstract][Full Text] [Related]
33. Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system.
Mariani SM; Matiba B; Sparna T; Krammer PH
J Immunol Methods; 1996 Jun; 193(1):63-70. PubMed ID: 8690931
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit.
Bernassola F; Scheuerpflug C; Herr I; Krammer PH; Debatin KM; Melino G
Cell Death Differ; 1999 Jul; 6(7):652-60. PubMed ID: 10453076
[TBL] [Abstract][Full Text] [Related]
35. Fas ligand deficiency in HIV disease.
Sieg S; Smith D; Yildirim Z; Kaplan D
Proc Natl Acad Sci U S A; 1997 May; 94(11):5860-5. PubMed ID: 9159165
[TBL] [Abstract][Full Text] [Related]
36. The regulation of CD95 ligand expression and function in CTL.
Li JH; Rosen D; Ronen D; Behrens CK; Krammer PH; Clark WR; Berke G
J Immunol; 1998 Oct; 161(8):3943-9. PubMed ID: 9780162
[TBL] [Abstract][Full Text] [Related]
37. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
38. Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents.
Böhler T; Bäumler C; Herr I; Groll A; Kurz M; Debatin KM
Pediatr Infect Dis J; 1997 Aug; 16(8):754-9. PubMed ID: 9271036
[TBL] [Abstract][Full Text] [Related]
39. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis.
Sträter J; Wellisch I; Riedl S; Walczak H; Koretz K; Tandara A; Krammer PH; Möller P
Gastroenterology; 1997 Jul; 113(1):160-7. PubMed ID: 9207274
[TBL] [Abstract][Full Text] [Related]
40. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system.
Li-Weber M; Krammer PH
Semin Immunol; 2003 Jun; 15(3):145-57. PubMed ID: 14563113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
